Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VQ4G
|
|||
| Former ID |
DNC003835
|
|||
| Drug Name |
N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
|
|||
| Synonyms |
CHEMBL61092; 1046-70-4; SCHEMBL8288058; CTK0D7916; DTXSID50658232; BDBM50143356; 1,4-Butanediamine, N'-9-acridinyl-N,N-diethyl-; N''-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27N3
|
|||
| Canonical SMILES |
CCN(CC)CCCCNC1=C2C=CC=CC2=NC3=CC=CC=C31
|
|||
| InChI |
1S/C21H27N3/c1-3-24(4-2)16-10-9-15-22-21-17-11-5-7-13-19(17)23-20-14-8-6-12-18(20)21/h5-8,11-14H,3-4,9-10,15-16H2,1-2H3,(H,22,23)
|
|||
| InChIKey |
OALXTIRPFIITPC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1046-70-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Oxytocin signaling pathway | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
| WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1913-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.